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A B S T R A C T
Spontaneous, recurrent spreading depolarizations (SD) are increasingly more appreciated as a pathomechanism
behind ischemic brain injuries. Although the prostaglandin F2α - FP receptor signaling pathway has been
proposed to contribute to neurodegeneration, it has remained unexplored whether FP receptors are implicated in
SD or the coupled cerebral blood flow (CBF) response. We set out here to test the hypothesis that FP receptor
blockade may achieve neuroprotection by the inhibition of SD. Global forebrain ischemia/reperfusion was in-
duced in anesthetized rats by the bilateral occlusion and later release of the common carotid arteries. An FP
receptor antagonist (AL-8810; 1 mg/bwkg) or its vehicle were administered via the femoral vein 10 min later.
Two open craniotomies on the right parietal bone served the elicitation of SD with 1 M KCl, and the acquisition
of local field potential. CBF was monitored with laser speckle contrast imaging over the thinned parietal bone.
Apoptosis and microglia activation, as well as FP receptor localization were evaluated with im-
munohistochemistry. The data demonstrate that the antagonism of FP receptors suppressed SD in the ischemic
rat cerebral cortex and reduced the duration of recurrent SDs by facilitating repolarization. In parallel, FP re-
ceptor antagonism improved perfusion in the ischemic cerebral cortex, and attenuated hypoemic CBF responses
associated with SD. Further, FP receptor antagonism appeared to restrain apoptotic cell death related to SD
recurrence. In summary, the antagonism of FP receptors (located at the neuro-vascular unit, neurons, astrocytes
and microglia) emerges as a promising approach to inhibit the evolution of SDs in cerebral ischemia.
1. Introduction
Spreading depolarization (SD), a remarkable neurophysiological
phenomenon, has been recognized to be central to neurodegeneration
after acute brain injury (Hartings et al., 2017a). Notably, recurrent SDs
have been associated with early focal brain injury and delayed ischemic
neurological deficit after subarachnoid hemorrhage (Dreier et al., 2006;
Hartings et al., 2017b; Eriksen et al., 2019), and may provoke un-
favorable hemodynamic and metabolic conditions in the cerebral cortex
of malignant hemispheric stroke patients (Woitzik et al., 2013;
Pinczolits et al., 2017).
SD corresponds to an abrupt, near complete breakdown of the
https://doi.org/10.1016/j.nbd.2020.104780
Received 4 December 2019; Received in revised form 21 January 2020; Accepted 24 January 2020
Abbreviations: 2VO, bilateral occlusion of the common carotid arteries, 2-vessel occlusion; aCSF, artificial cerebrospinal fluid; ADR, alpha-to-delta ratio; ANOVA,
analysis of variance; AUC, area under the curve; BPM, beat per minute; BSA, bovine serum albumin; CBF, cerebral blood flow; CC3, cleaved caspase-3; CL, con-
tralateral; COX-2, cyclooxygenase-2; DAB, diaminobenzidine; DC, direct current; DMSO, dimethyl sulfoxide; ECoG, electrocorticogram; GFAP, glial fibrillary acidic
protein; Iba1, ionized calcium-binding adapter molecule; IL, ipsilateral; LSCI, laser speckle contrast imaging; MABP, mean arterial blood pressure; NeuN, neuronal
nuclear protein; OGD, oxygen-glucose deprivation; PBS, phosphate buffer saline; PFA, paraformaldehyde; PGE2, prostaglandin E2; PGF2α, prostaglandin F2α; SD,
spreading depolarization
⁎ Corresponding author at: Department of Medical Physics and Informatics, Faculty of Medicine, and Faculty of Science and Informatics, University of Szeged,
Korányi fasor 9, H-6720 Szeged, Hungary.
E-mail address: farkas.eszter.1@med.u-szeged.hu (E. Farkas).
1 These Authors contributed equally to the work.
Neurobiology of Disease 137 (2020) 104780
Available online 25 January 2020
0969-9961/ © 2020 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license 
(http://creativecommons.org/licenses/BY-NC-ND/4.0/).
T
transmembrane ion gradients and a near-complete sustained neuronal
and glial depolarization that propagates in the cerebral gray matter at a
slow rate (2–8 mm/min) (Leão, 1944; Somjen, 2001). The restoration of
the membrane potential requires the mobilization of metabolic re-
sources for the operation of ATP-dependent ion pumps (e.g. the Na+/
K+ ATP-ase). This need is met by a profound hyperemic cerebral blood
flow (CBF) response coupled to SD in otherwise non-compromised
tissue (Ayata and Lauritzen, 2015). The coupling between SD and local
CBF becomes impaired under ischemia, which may create a metabolic
supply-demand mismatch, a subsequent energy crisis superimposed on
prevailing ischemia, and facilitated tissue injury (Dreier, 2011).
The current understanding of the relevance of SD in acute brain
injuries posits that SD is harmful because its recurrence imposes an
overwhelming metabolic challenge and triggers excitotoxicity in is-
chemic brain tissue (Hartings et al., 2017a; Shuttleworth et al., 2019).
Consequently, the suppression of SD, or the improvement of the he-
modynamic response to SD have been considered as therapeutic ap-
proaches in the post-operative care of brain injury patients (Helbok
et al., 2019). Appreciating the cellular mechanisms of neurodegenera-
tion triggered by SD (Hertelendy et al., 2019), the pharmacological
modulation of SD has targeted (i) NMDA receptor-based glutamate
excitotoxicity with the non-selective NMDA receptor blocker ketamine
(Sánchez-Porras et al., 2017; Reinhart and Shuttleworth, 2018; Carlson
et al., 2018), (ii) neurotoxic or vasoconstrictive intracellular Ca2+ ac-
cumulation by the L-type voltage-gated Ca2+ channel blocker nimodi-
pine (Dreier et al., 2002; Carlson et al., 2019; Szabó, 2019), or (iii) SD-
coupled spreading ischemia by the anti-coagulant and vasodilator agent
cilostazol (Sugimoto et al., 2018).
We have gathered experimental evidence that prostaglandin sig-
naling may be an additional target for neuroprotection in the context of
SD (Varga et al., 2016). We have shown previously, that the antagonism
of the EP4 receptor of prostaglandin E2 (PGE2) worsened the char-
acteristics of SD (Varga et al., 2016). SD induces the release of ara-
chidonic acid in the nervous tissue (Lauritzen et al., 1990) and the
cyclooxygenase-based synthesis of a wide range of vasoactive arachi-
donic acid metabolites (Shibata et al., 1992). As such, the concentration
of both the vasodilator PGE2 and the vasoconstrictor prostaglandin-F2α
(PGF2α) was found to increase twofold in the cerebrospinal fluid in
response to experimentally induced SD in rabbits. Treatment with the
non-selective cyclooxygenase inhibitor indomethacin augmented the
SD-coupled hyperemia, indicative of the dominant involvement of va-
soconstrictive prostaglandins in the mediation of the CBF response
(Shibata et al., 1992). Later, the more selective pharmacological in-
hibition of the EP4 receptor of PGE2 reduced the magnitude of hy-
peremia and augmented post-SD oligemia (Varga et al., 2016), while
the antagonism of the FP receptor of PGF2α decreased the amplitude of
post-SD oligemia in the otherwise intact rat cerebral cortex (Gariepy
et al., 2017). These experimental data together suggest a fine balance of
EP4 and FP receptor activation in the regulation of the CBF response to
SD, and importantly, the vasoconstrictive contribution of the PGF2α –
FP receptor signaling.
The PGF2α – FP receptor signaling cascade has been implicated in
ischemia/reperfusion-induced neurodegeneration, as well. First, the
level of PGF2α was shown to increase in the brain tissue and the cer-
ebrospinal fluid in animal models of cerebral ischemia (Gaudet and
Levine, 1980; Katz et al., 1988). Later, neurological deficit and ischemic
lesion volume were found reduced in FP receptor knock-out compared
to wild type mice (Saleem et al., 2009), and the pharmacological an-
tagonism of FP receptors also resulted in smaller infarct volume and
better functional outcome in a mouse model of focal cerebral ischemia
(Kim et al., 2012). Further, the antagonism of FP receptors in an ex-
perimental model of traumatic brain injury – a disorder in which SD has
been implicated (Hartings et al., 2011a,b; Toth et al., 2016) – reduced
the injury-related neurological deficit (Glushakov et al., 2013). The FP-
receptor-linked neurodegenerative signaling is likely Ca2+-dependent,
because the agonism of FP receptors increased intracellular Ca2+
concentration in cultured neurons (Kim et al., 2012), although the
presence of FP receptors on neuronal membranes have not been un-
equivocally confirmed. Indeed, the comprehensive localization and
distribution of FP receptors in the central nervous system is still to be
established.
The synthesis of the experimental results on the implication of
PGF2α – FP receptor signaling in ischemic brain injury and SD
prompted us to hypothesize that SD must be a central mechanism in FP
receptor activation-related ischemic neuronal injury. We postulate that
neuronal FP receptors are activated by PGF2α accumulating with SD,
which may directly promote neurodegeneration. Simultaneously, cer-
ebrovascular PGF2α – FP receptor signaling in response to SD may
potentiate vasoconstriction, and thereby impede neuronal survival
under penumbra-like ischemic conditions. To test the hypotheses, we
carefully analyzed the characteristics of SD and the coupled CBF re-
sponse under pharmacological FP receptor antagonism in comparison
with control conditions in the ischemic rat brain. Then, the degree of
ischemia/reperfusion injury was evaluated with immunocytochemistry
in perfusion-fixed brain slices of the animals. Also, we set out to identify
which distinct elements of the nervous tissue carry FP receptors, to
confirm potential sites of action. Taken together, the ultimate purpose
of this study has been to evaluate the protective potential of FP receptor
antagonism against SD and the related neurodegeneration.
2. Materials and methods
2.1. Animals
The experimental procedures were approved by the National Food
Chain Safety and Animal Health Directorate of Csongrád County,
Hungary. The procedures were performed according to the guidelines of
the Scientific Committee of Animal Experimentation of the Hungarian
Academy of Sciences (updated Law and Regulations on Animal
Protection: 40/2013. (II. 14.) Gov. of Hungary), following the EU
Directive 2010/63/EU on the protection of experimental animals, and
in accordance with the ARRIVE guidelines.
Young adult, male Sprague-Dawley rats (Charles River Laboratories,
342 ± 40 g, n = 19) were used in this study. Standard rodent chow
and tap water were supplied ad libitum. The animals were housed
under constant temperature, humidity, and lighting conditions (23 °C,
12:12 h light/dark cycle, lights on at 7 a.m.).
The designed rate of the two groups (untreated and treated) was 1.
The necessary number of animals in each group was at least 7 to sup-
port 80% power (β = 20% risk of second species), which was calcu-
lated based on the standard deviation of electrophysiological and he-
modynamic parameters in earlier studies and the presumed differences
between the means of the two groups. The calculations were made in
software PS 3.1.2 version (Vanderbilt University, USA) and were also
tested in software GPower 3.1 (Heinrich Heine University of
Düsseldorf).
2.2. Surgical procedures
Animals were anesthetized with 1.5–2% isoflurane in N2O:O2 (2:1)
and were allowed to breathe spontaneously through a head cone during
the experiment. Body temperature was kept at 37.2 °C by a feedback-
controlled heating pad (Harvard Apparatus, USA). Atropine was ad-
ministered (0.1%, 0.05 ml; i.m) as premedication in order to avoid the
production of airway mucus. Mean arterial blood pressure (MABP) and
heart rate were monitored with a Mikro-Tip pressure catheter inserted
to the left femoral artery (Mikro-Tip BP Foundation System,
ADInstruments, Australia). The adjacent femoral vein was cannulated
for drug administration. The respiratory rate was monitored with a
piezo-electric pulse transducer (Pulse Transducer (DIN),
ADInstruments, Australia) attached to the chest of the animal. For the
later initiation of incomplete global forebrain ischemia, a midline
D.P. Varga, et al. Neurobiology of Disease 137 (2020) 104780
2
incision was made in the neck and each common carotid artery was
carefully looped around with a surgical thread. Lidocaine (1%) was
used for local anesthesia. All rats were fixed by their head in a prone
position in a stereotaxic apparatus. The scalp was opened, and the
temporal muscle was gently retracted from the temporal bones. Two
adjacent craniotomies (5 mm lateral from the sagittal suture, −1, −5
caudal from the bregma) were prepared on the right parietal bone with
a dental drill (ProLab Basic, Bien Air 810, Switzerland) (Fig. 1). The
dura was then carefully opened in each craniotomy. The caudal window
was used for electrophysiological monitoring, while the rostral window
served SD elicitation. The cranial windows were constantly kept moist
by artificial cerebrospinal fluid (aCSF; mM concentrations: 126.6 NaCl,
3 KCl, 1.5 CaCl2, 1.2 MgCl2, 24.5 NaHCO3, 6.7 urea, 3.7 glucose bub-
bled with 95% O2 and 5% CO2 to achieve a constant pH of 7.4). The rest
of the bone was thinned, including the medial part of the contralateral
parietal bone (Fig. 1) in order to visualize CBF changes with laser
speckle contrast imaging (LSCI) (PeriCam PSI HR, Perimed AB,
Sweden).
Two of the rats were excluded because they developed respiratory
failure under anesthesia and died as a consequence during the experi-
mental protocol. One additional animal was terminated before the be-
ginning of the experimental protocol because the preparation of the
cranial window caused extensive hemorrhage. This resulted in group
sizes of 7 and 8 rats, AL-8810-treated and control, respectively.
2.3. Recording of electrophysiological variables and imaging of cerebral
blood flow
For the acquisition of the electrocorticogram (ECoG) and slow cor-
tical or direct current (DC) potential, a saline-filled (120 mM NaCl)
glass capillary microelectrode (20 μm outer tip diameter) was inserted
700 μm deep into the right somatosensory cortex. An Ag/AgCl reference
electrode was implanted under the skin of the animal's neck. The
electrophysiological signals were recorded via a high input impedance
pre-amplifier (NL102GH, NeuroLog System, Digitimer Ltd., United
Kingdom), connected to a differential amplifier (NL106, NeuroLog
System, Digitimer Ltd., United Kingdom) with associated filter (ECoG
filtered in wideband scale: 0.5–35 Hz, DC filtered in DC
mode;< 0.5 Hz) and conditioner systems (NL125, NL144, NL530,
NeuroLog System, Digitimer Ltd., United Kingdom). Line frequency
noise (50 Hz) was removed by a high-quality noise eliminator
(HumBug, Quest Scientific Instruments Inc., Canada). The electrical
signals along with MABP and respiration were digitalized by a
PowerLab data acquisition device (ADInstruments, Australia) con-
trolled through a dedicated software LabChart 8 (ADInstruments,
Australia) at a sampling frequency of 2 kHz.
Laser speckle contrast imaging was used to record SD-associated
changes in local CBF over the bilateral somatosensory cortex under
thinned cranial bones. Heatmap images of CBF were created in the
software PIMSoft (Software Version 1.3, Perimed AB, Sweden), dedi-
cated to the LSCI apparatus PeriCam PSI HR (Perimed AB, Sweden).
Three regions of interest (0.01 mm2 each) were positioned over the
right parietal cortex (posterior, lateral, anterior) ipsilateral to SD in-
duction to extract local CBF variations from the CBF image sequence
(Fig. 4A). Arbitrary perfusion units were converted to relative CBF
changes offline, with respect to the first 5 min of baseline (100%) and
averaged biological zero (0%) taken from previous experiments.
2.4. Experimental protocol
After 10 min of baseline period, both common carotid arteries were
occluded (2-vessel occlusion, 2VO) by pulling and securing the surgical
threads looped around the vessels. Successful 2VO was confirmed by a
sharp drop of CBF. The FP-receptor antagonist AL-8810 (1 mg/bwkg,
dissolved in 0.1% dimethyl sulfoxide in physiological saline, Sigma-
Aldrich, USA) or its vehicle were bolus administered i.v. in 1 ml volume
10 min after 2VO onset (Fig. 1). The dose of AL-8810 was selected to
correspond to a dose found effective to reduce ischemic brain infarct
volume in a previous experimental study, where AL-8810 was injected
i.v. at 1 or 10 mg/bwkg (Kim et al., 2012). Since the lower con-
centration was found effective (Kim et al., 2012), and lower drug
concentrations are expected to deliver potential side effects less likely,
we designed our experiments accordingly. SDs were triggered with a
1 M KCl-soaked cotton ball placed on the cortex (Farkas et al., 2011)
20 min after drug infusion (Fig. 1.). The cotton ball was removed and
the craniotomy rinsed with aCSF after two subsequent SD events, pro-
voked at an inter-SD interval of at least 15 min. Next, the KCl-soaked
cotton ball was left on the brain surface for 60 min to induce clusters of
SDs. Finally, reperfusion was initiated by releasing the carotid arteries,
and the animals were kept under light sedation (1% isoflurane) for an
additional 3 h in order for ischemic tissue injury to mature.
2.5. Tissue processing and immunocytochemistry
The animals were transcardially perfused with ice-cold physiolo-
gical saline followed by 4% paraformaldehyde (PFA) under deep
chloral hydrate anesthesia (5%, i.p., 500 mg/bwkg) at the end of the
experimental protocol. The brains were removed, stored in 4% PFA at
4 °C overnight, and cryoprotected in 30% sucrose in phosphate buffered
saline (PBS). Coronal, 20-μm-thick forebrain sections were cut with a
freezing microtome (Leica CM 1860 UV, Leica, Germany). Slices were
selected for the permanent immunocytochemical staining of cleaved
caspase-3 (CC3), the immunofluorescent co-localization of CC3 with the
neuron marker neuronal nuclear protein (NeuN) or the astrocyte
marker glial fibrillary acidic protein (GFAP), or the immunofluorescent
co-localization of FP receptors with neural glial, as well as
Fig. 1. Graphical illustration of the experimental protocol. A, In the preparation, black circles indicate the position of the two open cranial windows (1 mm caudal
from bregma and 5 mm lateral from the sagittal suture), created for the recording of the electrocorticogram (ECoG) and direct current (DC) potential (caudal
window) and the experimental elicitation of spreading depolarizations (SD) with KCl (rostral window). The dorsal cranium thinned for the monitoring of cerebral
blood flow (CBF) with laser speckle contrast imaging (LSCI) is shaded gray. B, The schematic drawing illustrates the subsequent phases of the experimental protocol.
After the initiation of global forebrain ischemia, the FP receptor antagonist AL-8810 or its vehicle, 0.1% dimethyl sulfoxide (DMSO) was bolus injected i.v..
Subsequently, SDs were triggered – in a controlled and then a continuous manner – at the ipsilateral cerebral cortex. After a period of reperfusion, the brains were
removed for histological examination.
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cerebrovascular elements.
First, apoptotic cell injury was characterized with cleaved caspase-3
(CC3) and the activation of microglia with ionized calcium-binding
adapter molecule (Iba1) immunolabeling on selected coronal slices
(bregma +1, −3.14 and −6.04 mm, Paxinos and Watson atlas co-
ordinates; two slices per plane). Endogenous peroxidases were blocked
with 5% H2O2, nonspecific protein-binding sites were blocked with 5%
normal goat serum (Merck, Kenilworth, USA), and slices were per-
meabilized with 0.5% Triton X-100 (Merck, Kenilworth, USA) in Tris-
buffered saline (TBS). Slices were incubated with rabbit anti-CC3 or
anti-Iba1 primary antibody (CC3: Abcam, ab13847, 1:300; Iba1: rabbit,
FujiFilm Wako, NCNP24, 1:3000) overnight at 4 °C. The subsequent
steps of incubation included an enhancer reagent for 1 h at room
temperature, and horseradish-peroxidase-linked secondary antibody for
3 h at room temperature, both being components of the Polink-2 Plus
HRP Detection Kit (for rabbit primary antibody with diaminobenzidine
(DAB) chromogen, D39–18, GBI Labs, USA). The staining was visua-
lized with DAB. The slices were mounted on microscopic slides with
Eukit® (Merck, USA) and digitally recorded either with a microscope
slide scanner (Zeiss Mirax Midi Slide Scanner, Carl Zeiss MicroImaging
GmbH, Germany) operated by a CaseViewer software (3D Histech Ltd.,
Hungary), or a Nikon-DS Fi3 camera attached to a Leica DM 2000 Led
light microscope (Leica Microsystems GmbH, Germany). The CC3-la-
beled slides were evaluated by manual cell counting with the
CellCounter plugin of ImageJ by two observers blind to the experi-
mental design (Wayne Rasband, NIH). In the Iba1-immunolabeled
slices, cells were counted, and microglia activation was characterized
with a ramification index exactly as reported earlier (Tóth, 2020)
Next, the cell types of the nervous tissue involved in apoptotic cell
death were identified by the representative co-localization of cleaved
caspase-3 with NeuN or GFAP. Antigens were retrieved with 10-minute-
long boiling in citrate buffer (pH 5, 95 °C, 300 rpm). Slices were per-
meabilized with 0.2% Triton X-100 in PBS for 30 min. Non-specific
protein-binding sites were blocked with 3% bovine serum albumin
(BSA) for 1 h at room temperature. Slices were incubated with primary
antibodies overnight at 4 °C (anti-cleaved caspase-3: rabbit, Cell
Signaling, #9661, 1:500; anti-GFAP: mouse, Sigma, G3893, 1:10000;
anti-NeuN: mouse, Millipore, MAB377, 1:500; in 1% BSA in PBS).
Secondary antibodies were applied for 1 h at room temperature (anti-
rabbit Alexa 594; goat, Jackson Laboratories, 1:500; anti-mouse Alexa
488, goat, Jackson Laboratories, 1:500; in 1% BSA in PBS). Slices were
mounted with Fluoromount-G with DAPI (Thermo Fisher Scientific,
USA), for the additional visualization of cell nuclei. Representative
photomicrographs were taken of the somatosensory cortex of a control
animal with a Leica SP5 inverted laser scanning confocal microscope
(TE2000U, Leica Microsystems GmbH, Germany) with 63× objective
with additional digital zoom giving. Confocal images were pieced to-
gether and processed in ImageJ.
Finally, in order to identify the cellular and subcellular localization
of FP receptors, the receptors were co-labeled with NeuN (neuronal
marker), GFAP (astrocyte marker), Iba1 (microglia marker), claudin-5
(endothelial cell marker) or alpha-actin (vascular smooth muscle cell
marker) in slices from a naïve animal. Antigens were retrieved with 10-
minute-long boiling in citrate buffer (pH 5; 95 °C, shaking at 300 rpm)
for claudin-5 co-staining. All slices were permeabilized with 0.2%
Triton X-100 in PBS for 30 min. Non-specific protein-binding sites were
blocked with 3% BSA for 1 h at room temperature. Slices were in-
cubated with primary antibodies overnight at 4 °C (anti-FP receptor:
rabbit, Abcam, ab203342, 1:100; anti-NeuN: mouse, Millipore,
MAB377, 1:500; anti-GFAP: mouse, Sigma, G3893, 1:10000; anti-Iba-1:
goat, Abcam, ab48004, 1:500; anti-claudin-5: mouse, Invitrogen,
#4C3C2, 1:100; in 1% BSA in PBS; anti-α-smooth muscle actin,
GeneTex, GTX73419, ready-to-use). Secondary antibodies were applied
for 1 h at room temperature (anti-rabbit STAR RED; goat, Abberior,
1:500; anti-mouse STAR 580, goat, Abberior, 1:500; anti-goat Alexa-
594, donkey, Thermo Fisher Scientific, 1:500; in 1% BSA in PBS). In
case of Iba-1 and FP double staining, the incubation with anti-goat
secondary antibody was followed by the incubation with goat anti-
rabbit antibody to avoid cross-reaction. Slices were mounted with
Fluoromount-G (Thermo Fisher Scientific). Representative confocal
images were taken of the somatosensory cortex with a Zeiss Axio
Observer Z1 inverted microscope (Carl Zeiss GmbH, Germany), and
pieced together and processed in ImageJ (National Institutes of Health,
Bethesda, Maryland, USA).
2.6. Data analysis
Physiological variables (i.e. DC potential and MABP) were si-
multaneously acquired, displayed live, and stored using a personal
computer equipped with the software LabChart 8 (ADInstruments,
Australia). the LSCI signal was acquired with PeriFlux System 5000
(Perimed AB, Sweden) and displayed live with PIMSoft. Raw LSCI re-
cordings were downsampled to 1 Hz before analysis. All data were then
converted and analyzed with the inbuilt instructions of the software
AcqKnowledge 4.2 for MP 150 (Biopac Systems, Inc., USA).
Blinding data analysis was intended by assigning codes to files and
recordings, which do not reveal the experimental condition (i.e., date of
the experiment). The SD events were first sorted according to their
duration and amplitude: With reference to regular transient SDs, pro-
longed SDs were noted when the depolarization was longer than 3 min
while the amplitude of the depolarization was similar to transient SDs
(> 10 mV), and incomplete SDs were identified by their amplitude
smaller than 10 mV, and their duration shorter than 30 s (Fig. 2A). For
all SD events, peak amplitude, duration at half amplitude, the rate of
depolarization and repolarization, and area under the curve (AUC) were
measured on the DC potential trace. The distribution of spectral power
of the ECoG recordings at alpha (8–13 Hz) and delta (1–4 Hz) frequency
bands were done with the software LabChart Pro (Labchart 8, National
Instrument, Australia). Total power for each frequency band was ex-
pressed for 60-s periods taken (i) before the induction of cerebral
ischemia, (ii) before the controlled elicitation of the 1st SD, (iii) before
continuous SD elicitation, and (iv) after reperfusion. As a proxy for
Fig. 2. Distinct types of spreading depolarization (SD) events, and their incidence during the phase of continuous elicitation. A, Traces depict DC potential changes
(lower trace, blue) and cerebral blood flow (CBF) responses (upper trace, red) representative of the different types of SDs. B, The incidence of various SD types are
given relative to the total number of SDs for the two experimental groups. Statistical association between Treatment and Types of SDs was analyzed with Chi-Square
Test (p = .01**). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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latter lesion formation, alpha-to-delta ratio (ADR) was calculated for
each time points (Menyhárt et al., 2015). SD frequency was also cal-
culated for recurrent events under continuous elicitation.
The CBF response to SD was first categorized as hyperemic (dom-
inating element of transient hyperemia), hypoemic (transient hypo-
perfusion alone) or no detectable CBF variation at a clear negative shift
(i.e. > 10 mV) of the DC potential (Bere et al., 2014). The SD-associated
hyperemia and hypoemia were then characterized by the peak ampli-
tude, and the duration of the transient CBF change. Data analysis was
shared among four independent investigators.
Data are given as mean ± stdev; parametric data are shown as bar
charts, while non-parametric data are presented with additional scatter
plots. The results were statistically analyzed with the software SPSS
(IBM SPSS Statistics for Windows, Version 22.0, IBM Corp.). Grubbs test
was applied to identify potential outliers. For the evaluation of statis-
tical significance, a repeated measure or a two-way analysis of variance
(ANOVA) model was used for data sets with normal distribution.
Tukey's HSD or Games–Howell post hoc test was used for group com-
parisons, whenever applicable. When the data did not fit normal dis-
tribution, non-parametric Mann-Whitney test was used. Frequency
distributions were evaluated with a Pearson's Chi-square test. Levels of
significance were defined as p < .05* and p < .01**. All relevant
statistical methods are given in each figure legend.
3. Results
3.1. Physiological parameters were unaltered by the AL-8810 treatment
In order to evaluate whether the intravenous administration of AL-
8810 had any potential impact on systemic physiological variables, we
analyzed arterial blood samples and cardiorespiratory parameters
(Table 1). The systemic physiological variables were within the normal
range throughout the experimental protocol. Ischemia increased MABP
(e.g. vehicle group: 85.3 ± 10.5 vs. 78.0 ± 9.3 mmHg, ischemia vs.
baseline) and arterial pO2 (e.g. vehicle group: 110.9 ± 11.8 vs.
105.4 ± 15.1 mmHg, ischemia vs. baseline), as in other experimental
models of cerebral ischemia (Menyhárt et al., 2015; Lückl et al., 2018).
The treatment with AL-8810 did not exert any detectable impact on the
examined variables (Table 1).
3.2. AL-8810 reduced depolarization time and promoted early recovery
after SD
The occurrence of SD clusters or prolonged depolarizations, and the
long cumulative duration of recurrent SDs indicate and predict the
development of secondary ischemic brain injury after an acute insult
(Dreier et al., 2006; Hartings et al., 2017a; Shuttleworth et al., 2019).
We have demonstrated earlier that the inhibition of the EP4 receptor of
PGE2 causes the unfavorable elongation of SD in the ischemic cerebral
cortex (Varga et al., 2016). Here we explored whether the antagonism
of the FP receptor of PGF2α modulates the occurrence or duration of
SDs beneficially.
SD occurrence was confirmed with electrophysiology and LSCI in
the ipsilateral cortex, but no SD propagation to the contralateral side
was seen in the CBF maps. In case of the initial, controlled elicitation,
all SDs were transient with no statistical difference in the DC potential
signature between the two groups (i.e. amplitude: −18.3 ± 2.7 vs.
−18.0 ± 2.6 mV, AL-8810 vs. vehicle; duration at half amplitude:
55 ± 25 vs. 56 ± 19 s, AL-8810 vs. vehicle).
Subsequent to controlled SD elicitation, clusters of SDs were trig-
gered with continuous KCl exposure. Each of these recurrent SDs was
categorized as transient, prolonged or incomplete, on the basis of their
DC potential signature acquired at the implanted electrode (Fig. 2A).
Then their incidence relative to the total number of recurrent SDs was
expressed for the AL-8810 and the vehicle-treated groups separately
(Fig. 2B). Incomplete SDs typically occurred towards the end of the
continuous SD elicitation. The antagonism of FP receptors with AL-
8810 prevented the evolution of prolonged SDs (0 vs. 15%, AL-8810 vs.
vehicle), and achieved a complementary increase in the incidence of
incomplete SDs (25 vs. 5%, AL-8810 vs. vehicle). At the same time, the
share of regular transient SDs of all recurrent events remained com-
parable between the two experimental groups (75 vs. 80%, AL-8810 vs.
vehicle) (Fig. 2B).
Detailed, quantitative analysis of recurrent SDs focused on transient
events (Fig. 3). Similar to the controlled SDs, the amplitude of the
clustered SDs was similar in the two experimental groups
(−17.5 ± 2.4 vs. −16.9 ± 3.1 mV, AL-8810 vs. vehicle). Never-
theless, AL-8810 treatment accelerated the repolarization after SDs
(0.84 ± 0.4 vs. 0.45 ± 0.22 mV/s, AL-8810 and vehicle) (Fig 3A1).
Accordingly, the average duration of an SD at half amplitude (30 ± 10
vs. 56 ± 14 s, AL-8810 vs. vehicle) (Fig. 3A2), as well as the cumu-
lative duration of recurrent transient SDs was found shorter (304 ± 71
vs. 577 ± 154 s, AL-8810 vs. vehicle) in the AL-8810-treated com-
pared to the control group. In line with these data, the magnitude of
individual SDs expressed as AUC was reduced in the AL-8810 treated
group compared to control (585 ± 192 vs. 942 ± 251 mV*s; AL-8810
vs. vehicle) (Fig 3A3). Taken together, FP receptor blockade prevented
the development of prolonged depolarization, accelerated repolariza-
tion, and shortened the cumulative duration of clustered, recurrent SDs.
3.3. AL-8810 increased electrocorticographic alpha-to-delta ratio in the
reperfused cortex
Lowering electrocorticographic alpha-to-delta ratio (alpha power/
delta power, ADR) has been proposed as a sensitive and selective tool to
predict the evolution of delayed cerebral ischemia after aneurismal
subarachnoid hemorrhage (Claassen et al., 2004; Rots et al., 2016; Yu
et al., 2019). In addition, delayed cerebral ischemia has been linked to
SD (Dreier et al., 2006; Dreier et al., 2009). Therefore, we calculated
ECoG power for alpha (8–13 Hz) and delta (1–4 Hz) frequency bands
and expressed ADR for 4 selected time points over the experimental
protocol (Fig. 3B1). As expected, ADR taken prior to ischemia induction
and the initiation of AL-8810 treatment was comparable for the two
experimental groups (0.67 ± 0.20 and 0.63 ± 0.29; AL-8810 and
vehicle). ADR remained similar 30 min after the induction of ischemia
and the administration of AL-8810 (0.81 ± 0.36 and 0.65 ± 0.26; AL-
Table 1
Physiological variables.
Pharmacological
treatment
n Body weight (g) Time of
sampling
MABP (mmHg) Heart rate (BPM) Rate of respiration
(Hz)
Arterial pO2 (mmHg) Arterial pCO2
(mmHg)
Vehicle 8 335 ± 48 Before 2VO 78.0 ± 9.3 352 ± 49 1.19 ± 0.12 105.4 ± 15.1 41.6 ± 3.2
After 2VO 85.3 ± 10.5* 328 ± 58 1.12 ± 0.13 110.9 ± 11.8* 38.4 ± 7.2
AL-8810 7 353 ± 38 Before 2VO 78.1 ± 7.7 339 ± 22 1.31 ± 0.19 102.6 ± 16.1 38.5 ± 3.0
After 2VO 83.5 ± 8.5* 334 ± 28 1.22 ± 0.24 118.6 ± 27* 38.6 ± 2.3
Data are given as mean ± stdev. A two-way ANOVA model (factors: ischemia and treatment) was used for statistical analysis. Ischemia was found to increase blood
pressure and arterial pO2 significantly (p < .05*). Abbreviations: 2VO, permanent, bilateral occlusion of the common carotid arteries (“two-vessel occlusion”); BPM,
beat per minute; MABP: mean arterial blood pressure.
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8810 and vehicle). After the controlled elicitation of two SDs, ADR
reduced in both experimental groups equally (0.45 ± 0.23 and
0.36 ± 0.22; AL-8810 and vehicle). Finally, 5 min after the initiation
of reperfusion and the cessation of clusters of recurrent SDs, ADR in-
creased selectively in the AL-8810 treated group (0.66 ± 0.29 vs.
0.35 ± 0.17; AL-8810 vs. vehicle) (Fig. 3B2). Thus, ADR – a perceived
predictor of late ischemic injury – was improved during early reperfu-
sion by AL-8810 treatment.
3.4. AL-8810 augmented hyperemia and attenuated hypoperfusion with SD
The CBF response to SD consists of at least three distinct elements
including a brief, early hypoperfusion, a subsequent, substantial hy-
peremia, and a final, long lasting oligemia (Ayata and Lauritzen, 2015).
The pharmacological augmentation of the CBF response to SD in the
service of neuroprotection is a realistic goal, because insufficient hy-
peremia and especially the occurrence of spreading ischemia (i.e. the
early hypoperfusion element of the CBF response overriding the hy-
peremic component) delays repolarization and reduces the viability of
penumbra tissue (Dreier, 2011; Hartings et al., 2017a).
The spatial resolution offered by LSCI in our experiments enabled a
comprehensive analysis of the CBF response to SD. We concentrated our
detailed analysis on recurrent SDs, which emerged as regular, transient
negative DC potential shifts (amplitude> 10 mV, duration< 3 min) at
the electrode implanted. First, with the aid of placing multiple regions
of interest (ROIs) on the CBF videos (Fig. 4A), we noted that the kinetics
of the CBF response associated to a given SD may alter over the course
of SD propagation. Hyperemic CBF response was most frequently en-
countered at the ROI positioned over the open cranial window in-
corporating the electrode (lateral in Fig. 4A–C; 92 and 100%, AL-8810
and vehicle). The CBF response to the same SD often escaped detection
(“no CBF response”) at ROIs over the thinned parietal bone (anterior:
31 and 48%, posterior: 35 and 26%, AL-8810 and vehicle). Finally, the
CBF response transformed occasionally to hypoperfusion at the anterior
ROI placed over the medial fronto-parietal cortex, particularly in the
control group (12 and 22%, AL-8810 and vehicle) (Fig. 4A–B).
The detailed, quantitative analysis of the hyperemic CBF responses
revealed that AL-8810-treatment elevated baseline CBF prior to SD (e.g.
lateral ROI: 73.0 ± 13.8 vs. 56.8 ± 6.3%; AL-8810 vs. vehicle), and
therefore augmented the absolute amplitude of the SD-coupled hyper-
emia, as well (e.g. lateral ROI: 104.1 ± 25.0 vs. 76.0 ± 8.6%, AL-
8810 vs. vehicle) (Fig. 4D). Further, AL-8810 treatment attenuated
hypoemic CBF responses, which was reflected by the smaller relative
amplitude of the hypoperfusion transients (−5.4 ± 1.7 vs
−14.0 ± 1.8 pp., AL-8810 vs. vehicle) (Fig. 4E). Also, progressive
perfusion deficit during continuous SD elicitation was less prominent in
the AL-8810 treated group compared to control, resulting in higher CBF
prior to the initiation of reperfusion (68.2 ± 14.5 vs. 58.6 ± 9.6%,
AL-8810 vs. vehicle). Finally, the rate of propagation of the SD coupled
CBF response was accelerated under AL-8810 treatment compared to
the control condition (3.0 ± 0.7 vs. 2.4 ± 0.5 mm/min, AL-8810 vs.
vehicle) (Fig. 4F). Together these data demonstrate that AL-8810
treatment increased CBF in the ischemic cerebral cortex, and counter-
acted transient CBF reduction with SD.
3.5. AL-8810 treatment salvaged SD triggered apoptosis in the cortex, but
exerted no impact on microglia activation
Cleaved caspase-3 (CC3) has been a widely accepted apoptosis
marker in the nervous tissue (Fricker et al., 2018), which can be de-
tected confidently 3 h after the onset of reperfusion (Davoli et al., 2002;
Manabat et al., 2003).
Accordingly, we collected brain samples 3 h after the initiation of
reperfusion to assess the neuroprotective potential of AL-8810. CC3-
positive apoptotic cells were observed in striatal, hippocampal and
cortical areas in both experimental groups, albeit to a lesser degree in
the AL-8810-treated animals (Fig. 5A-B1). The immunofluorescent co-
localization of CC3 with NeuN and GFAP revealed that both neurons
and astrocytes were engaged in apoptosis (Fig. 5B2). With the antici-
pation of more extensive apoptosis in the hemisphere ipsilateral to SD
elicitation, the number of CC3-immunopositive cells was normalized to
the contralateral side. The quantitative approach suggested a significant
Fig. 3. The impact of AL-8810 treatment on the electrophysiological features of spreading depolarization (SD). A, The transient, negative DC potential shift indicating
SDs, triggered under continuous elicitation, is shown for each group (mean ± stdev). The rate of repolarization (A1), the duration at half amplitude (A2) and the area
under the curve (AUC) (A3) of the negative DC potential shift are depicted in bar charts. Dots denote individual values. Statistical analysis relied on Mann-Whitney
Rank sum test; **p < .01. B1, Representative DC potential traces and the corresponding electrocorticogram (ECoG) of a control (black) and an AL-8810 (blue)
treated animal. Note the typical depression of the ECoG with each SD. The ratio of the power of the frequency bands alpha and delta (alpha/delta ratio, ADR) was
calculated before the induction of cerebral ischemia (a), before the controlled elicitation of the 1st SD (b), before continuous SD elicitation (c), and after reperfusion
initiation (d). B2, ADR for the selected segments of the ECoG recordings. Statistical comparison relied on a repeated measures ANOVA (factor: treatment; p < .01**).
Pairwise comparisons for each time point were conducted with one-way ANOVA; *p < .05, AL-8810 vs. respective control. Sample size is indicated in each bar. (For
interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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Fig. 4. The impact of AL-8810 treatment on the cerebral blood flow (CBF) response to spreading depolarization (SD) under continuous elicitation. A, A representative
CBF map obtained with laser speckle contrast imaging demonstrates the 3 regions of interest (ROI), at which CBF variations were extracted: the lateral, the anterior,
and the posterior parietal cortex. The asterisk denotes the position of the glass capillary electrode implanted. B, Representative hyperemic and hypoemic CBF
responses to SD recorded from a control (black) and an AL-8810 treated (blue) animal. C, The table gives an overview of the occurrence of CBF response types relative
to all events at the distinct ROIs in the two experimental groups. Statistical association between ROI position and CBF response type was analyzed with a Pearson Chi-
Square Test (p < .01**). D, Baseline CBF prior to SD occurrence and the absolute amplitude of peak hyperemia coupled to SD in the anterior, lateral and posterior
parietal cortex. The base of each bar is set to the CBF level preceding the SD events. E, The relative amplitude of hypoperfusion. F, The average rate of propagation of
SDs calculated from the CBF maps for each group. Data in D-F are given as mean ± stdev; spehrical symbols in E-F represent individual values. Statistical analysis
relied on a repeated ANOVA (D) or Mann-Whitney Rank sum test (E–F); p < .05* and p < .01**. The number of events analyzed is indicated in each bar. (For
interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
Fig. 5. Neuroprotection achieved by FP receptor antagonism in the rat brain. A, Schematic coronal brain slices demonstrate gray matter regions in the ipsilateral (IL,
spreading depolarization elicitation on the background of ischemia) and contralateral (CL, ischemia alone) brain hemispheres, in which cleaved caspase-3 (CC3)
positive, apoptotic cells were quantitated: the striatum, the dentate gyrus of the hippocampus, and somatosensory parietal and occipital cortical areas (Som. and Occ.
cortex, respectively). B1, Representative photomicrographs taken of the occipital cortex ipsilateral to SD elicitation demonstrate that the number of CC3-labeled cells
(chromogen: diaminobenzidine) was reduced in the AL-8810-treated group compared to the control condition. B2, Fluorescent co-localization of CC3 labelling with
the cell nuclei (DAPI) of NeuN positive neurons (top) or GFAP-positive astrocytes (bottom) revealed that both neurons and astrocytes were engaged in apoptosis. C,
The CC3-positive cell count demonstrated that apoptosis was more prevalent in the hemisphere ipsilateral to SD elicitation, relative to the contralateral side. AL-8810
proved to exert neuroprotection in that the number of CC3-positive cells was similar in the two hemispheres in the treated group, particularly in the dentate gyrus and
the cerebral cortex. Data are given as mean ± stdev; sample size is given in each bar; statistical analysis was conducted using repeated measures ANOVA with
treatment as a factor (**p < .01). D, Representative images of Iba1 immunolabeled microglia. Photomicrographs were taken of the somatosensory cortex at
−3.14 mm from bregma. E, Microglial activation represented by the ramification of microglia was augmented in the ipsilateral compared to the contralateral
cerebral cortex, irrespective of treatment. Data are given as mean ± stdev; sample size is given in each bar; statistical analysis was conducted using a two-way
ANOVA model with lateralization and treatment as factors (*p < .05).
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neuroprotective effect of AL-8810 shown by the reduction of CC3 po-
sitive cell numbers in the ipsilateral relative to the contralateral
hemisphere (e.g. somatosensory and occipital cortices: 94.4 ± 12.6%
vs. 112.9 ± 7.0%; 104.3 ± 17.6% vs. 125,7 ± 17,7%, respectively,
AL-8810 vs. vehicle) (Fig. 5C). Overall, AL-8810 treatment appeared to
offer detectible neuroprotection measured early after ischemia/re-
perfusion induction.
Microgia activation is a rapid neuro-inflammatory response to in-
jury, which was previously suppressed with AL-8810, assessed days
after experimental traumatic brain injury (Glushakov et al., 2013). We
have observed intensive Iba1 immuno-labeling in the tissue samples
(Fig. 5D). While the number of labeled microglia was similar in the two
hemispheres irrespective of treatment (31 ± 7 and 28 ± 6, contra-
and ipsilateral), their arborization was less dense in the ipsilateral
hemisphere indicative of their increased activation (ramification index:
112.7 ± 55.4 vs. 174.2 ± 73.8, ipsi- vs. contralateral). The admin-
istration of AL-8810 did not exert any discernable impact on the ra-
mification of microglia processes (ramification index: 148.6 ± 63.8
and 138.3 ± 80.3, control and AL-8810) (Fig. 5D-E).
3.6. FP receptors were associated with neurons, astrocytes, microglia, and
cerebrovascular endothelial cells
FP receptors have been previously identified in brain synaptosomes
and microvessels in newborn and adult pigs (Li et al., 1993, 1994), and
cultured rat astrocytes (Kitanaka et al., 1994). Here we set out to vi-
sualize FP receptor presence on neuronal, glial (astrocyte and micro-
glia) and cerebrovascular (endothelial and smooth muscle cell) com-
partments as potential sites of AL-8810 action.
The co-localization of FP receptors with NeuN and GFAP confirmed
the localization of FP receptors predominantly in the nuclear envelope
of neurons (Fig. 6A), as well as in the perikaryon and perivascular
endfeet of astrocytes (Fig. 6B1-2). In addition, we observed a robust co-
localization of FP receptors with Iba1-labeled microglia (Fig. 6C). The
presence of FP receptors was also obvious in claudin-labeled cere-
bromicrovascular endothelial cells. However, we were not able to de-
tect FP receptors unequivocally in α-actin-labeled cerebrovascular
smooth muscle cells. In summary, FP receptor expression has been
confirmed in both neuronal, glial and vascular elements in the rat brain.
4. Discussion
Here we have explored the neuroprotective potential of the antag-
onism of the PGF2α FP receptor in experimental global forebrain
ischemia/reperfusion exacerbated by recurrent SDs.
Prostaglandin signaling has been in the center of pharmaceutical
research for decades. Importantly, experimental research suggested that
cyclooxygenase-2 enzyme (COX-2) inhibition may have therapeutic
potential in stroke (Candelario-Jalil and Fiebich, 2008). However, the
controversial action of repetitively administered COX-2 inhibitors on
platelet function may manifest in cardiovascular adverse effects in-
cluding thrombus formation and heart failure (Santilli et al., 2016). In
particular, in the context of ischemic brain injury, the use of COX-2
inhibitors prior to the occurrence of ischemic stroke was associated
with worse stroke outcome in patients (Schmidt et al., 2014). Since
COX-2 inhibition suppresses the synthesis of all types of prostaglandins
downstream to the enzyme (e.g. PGE2, PGF2α, thromboxanes), and
each prostaglandin may act on a number of receptor types mediating
complementary or opposing actions, subsequent efforts focused on the
selective modulation of distinct prostaglandin receptors. Indeed, the
EP1-EP4 receptors of PGE2 have been intensively studied and a wealth
of experimental data on their implication in ischemic brain injury have
been gathered (Andreasson, 2010). In the context of SD, EP4 receptors
appeared to be involved in the repolarization phase of SD in the is-
chemic rodent brain (Varga et al., 2016). Yet, the FP receptor of PGF2α
appears to have received considerably less attention (Zhang et al.,
2010; Sharif and Klimko, 2019), even though PGF2α concentration was
elevated in the brain tissue and the cerebrospinal fluid in animal models
of cerebral ischemia or SD (Gaudet and Levine, 1980; Katz et al., 1988;
Shibata et al., 1992), and PGF2α immunolabeling was found enhanced
after cerebral ischemia/reperfusion in the cerebral vascular wall and
hippocampal neurons of rats (Ogawa et al., 1987).
Our data demonstrate that the antagonism of the PGF2α FP re-
ceptors suppressed SD in the ischemic rat cerebral cortex (Fig. 2), re-
duced the duration of recurrent SDs by facilitating repolarization, and
augmented the recovery of ECoG during reperfusion (Fig. 3). Parallel
with the neurophysiological actions, FP receptor antagonism improved
perfusion in the ischemic cerebral cortex, and attenuated hypoemic CBF
responses associated with SD (Fig. 4). Further, FP receptor antagonism
appeared to curtail apoptotic cell death related to SD recurrence
(Fig. 5). Collectively, these findings are in agreement with a number of
previous reports of a research group, which presented that the phar-
macological antagonism or genetic knock-out of FP receptors reduced
ischemic infarct volume and improved functional outcome in pre-
clinical models of ischemic or traumatic brain injury (Saleem et al.,
2009; Kim et al., 2012; Glushakov et al., 2013). Since spontaneous,
recurrent SDs of long cumulative duration have been strongly im-
plicated in the pathophysiology of ischemic or traumatic brain injury
(Dreier et al., 2006; Hartings et al., 2017a), it is plausible that the fa-
cilitated recovery from SD achieved with FP receptor antagonism – as
Fig. 6. The cellular localization of FP receptors in the rat brain in representative fluorescent confocal microscopic images. A, FP receptors are associated to the
nuclear envelope of neuronal nuclear protein (NeuN)- positive neurons, B1, FP receptors are localized in the cytoplasm of astrocytes labeled with glial fibrillary acidic
protein (GFAP). B2, FP receptors are seen on GFAP-positive perivascular astrocytic endfeet. The vascular lumen is labeled with an asterisk. C, The co-localization of
FP receptors with the microglia marker ionized calcium-binding adapter molecule (Iba1).
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shown here – could have contributed to reduced lesion volume and less
severe functional deficit registered in the previous studies.
The ability of the nervous tissue to repolarize after SD is subject to
the metabolic status of the brain region involved in SD evolution. The
increasing severity of ischemia – and thus energy depletion of the tissue
– leads to sodium pump dysfunction and the failure of active ion
translocation between the intra- and extracellular compartments, and
delays the recovery of the resting membrane potential once SD has
occurred (Dreier, 2011). Since FP receptor antagonism in our experi-
ments markedly improved the perfusion of the ischemic cerebral cortex
(Fig. 4), it is conceivable that SD duration was shortened in the AL-
8810-treated animals (Fig. 3) because the tissue was metabolically less
compromised. Indeed, FP receptors at the periphery have been pre-
viously implicated in the regulation of vascular tone (Zhang et al.,
2010). FP receptors were associated with cultured smooth muscle cells
of a cell line derived from the embryonic rat aorta (Rice et al., 2008),
and the smooth muscle cells of preglomerular arterioles in the kidney
(Yu et al., 2009). The presence of FP receptors on vascular smooth
muscle cells was suggested to be the anatomical basis for FP receptor
linked vasoconstriction (Zhang et al., 2010). In addition to vascular
smooth muscle cells, venous endothelial cells of the peripheral vascular
network were also found to express FP receptors, which mediated
PGF2α-related vasorelaxation of the jugular and submental veins or
constriction of the human umbilical vein (Chen et al., 1995; Astin and
Stjernschantz, 1997; Zannoni et al., 2007). Finally, membranes pre-
pared from porcine cerebral microvessels were shown to host FP re-
ceptors (Li et al., 1994), and PGF2α applied to baboon isolated middle
cerebral artery rings was demonstrated to cause dilation at lower, and
constriction at higher concentration (Hayashi et al., 1985). We have
identified FP receptors associated with endothelial cells and perivas-
cular astrocytic endfeet of the neurovascular unit (Fig. 6), located at an
ideal position to contribute to cerebrovascular tone adjustment. Con-
sidering the experimental data accumulated on PGF2α-FP receptor
signaling in various vascular domains (Zhang et al., 2010), AL-8810
treatment in our study is suggested to have targeted – in part – the FP
receptors identified at elements of the neurovascular unit (Fig. 6). FP
receptor antagonism with AL-8810 presumably counteracted PGF2α-
linked vasoconstrictive tone, and, consequently, improved cere-
brocortical blood flow (Fig. 4).
Spreading ischemia coupled to SD that propagates across vulnerable
penumbra tissue has been considered particularly harmful (Dreier et al.,
1998; Dreier, 2011; Hartings et al., 2017a). We have observed a few
events of spreading ischemia near the site of SD elicitation, which
transformed to hyperemic CBF response along the direction of SD
propagation, with the increasing distance from the SD focus (Fig. 4B).
Spreading ischemia occurred near the site of SD elicitation possibly
because of the close proximity of the local administration of high
concentration KCl to evoke SDs, which has been shown to potentiate
SD-related hypoperfusion (Menyhárt et al., 2018). The occurrence of
spreading ischemia was less frequent under AL-8810 treatment, and
flow reduction with the observed events in the AL-8810 group was
considerably attenuated (Fig. 4E). This is considered as additional
evidence for the vasoconstrictive role cerebrovascular FP receptors may
fulfill in the mediation of the CBF response to SD.
The pharmacological inhibition of the FP receptors in our experi-
ments could have contributed to neuroprotection (Fig. 5) by targeting
neurons directly, as well. We have observed conspicuous FP receptor
labeling co-localized with neurons (Fig. 6A), which is consistent with
previous work that revealed the presence of FP receptors in synapto-
some preparations or cultured neurons (Li et al., 1993; Kim et al.,
2012). In support of the notion of direct neuroprotection by FP receptor
antagonism, AL-8810 proved to sustain the viability of cultured neurons
exposed to oxygen-glucose deprivation (OGD), reduced the production
of reactive oxygen species in OGD-stressed hippocampal slices, and
suppressed the OGD-induced rise of intraneuronal Ca2+ concentration
(Kim et al., 2012). It is noteworthy that intracellular Ca2+
concentration increases considerably with SD itself, and may prove
deleterious to neurons (Dietz et al., 2009). The Ca2+ overload with SD
was previously prevented by the NMDA receptor antagonist ketamine
(Reinhart and Shuttleworth, 2018). In addition, the L-type voltage-
gated Ca2+ channel blocker nimodipine shortened SD duration similar
to that achieved with ketamin (Szabó, 2019; Tóth, 2020). Therefore, it
may well be, that a potential reduction of intracellular Ca2+ content by
AL-8810 – as shown in neuronal cell culture (Kim et al., 2012) – could
have contributed directly to shortened SD duration (Fig. 3), and the
limitation of SD-related apoptosis (Fig. 5) as seen here.
The impact of AL-8810 treatment on microglia was evaluated here,
as well, because microglia were found to be richly endowed with FP
receptors (Fig. 6C). Previously, cultured rat microglia were shown not
to express FP receptor mRNA (Kitanaka et al., 1996), yet, later in-
vestigation identified functional FP receptors on transformed human
brain microglial cells (Xu et al., 2009). Further, in a model of experi-
mental TBI, AL-8810 administration attenuated microglia proliferation
days after the primary impact (Glushakov et al., 2013). In our experi-
ments, microglia activation proved to be enhanced in the cortex ipsi-
lateral to SD recurrence and the open cranial window, in addition to
that caused by ischemia alone. Our previous data have shown that the
surgical procedure itself (i.e. craniotomy) causes microglia activation,
and recurrent SDs enhance it further (Tóth, 2020), which amounts to
the difference observed between the ipsi- and contralateral hemispheres
in our preparations (Fig. 5D-E). AL-8810 did not alter microglia acti-
vation at this time point after the primary insult (i.e. 5 h after ischemia
onset, and 3 h after the occurrence of recurrent SDs). This suggests that
even though microglia abundantly express FP receptors (Fig. 6C), these
may not be functionally linked to microglia activation by endogenous
PGF2α in the acute/subacute phase of cerebral ischemia.
Recurrent SDs propagating over cerebrocortical zones under meta-
bolic stress have been increasingly more appreciated as the electro-
physiological correlate of and pathophysiological contributor to is-
chemic injury progression (Dreier, 2011; Hartings et al., 2017a,b).
Options for the pharmacological restriction of SD occurrence in acute
brain injury patients have been, therefore, explored and debated in-
tensively (Carlson et al., 2018, 2019; Sugimoto et al., 2018; Helbok
et al., 2019). The clinical evidence gathered so far supports the in-
hibition of SD with the non-selective NMDA receptor antagonist and
sedative agent ketamine (Hertle et al., 2012; Carlson et al., 2018), and
experimental research has identified the L-type voltage-gated Ca2+
channel blocker nimodipine, as an additional, promising candidate for
SD restriction (Dreier et al., 2002; Carlson et al., 2019; Szabó, 2019;
Tóth, 2020). Our current experiments together with our previous re-
sults (Varga et al., 2016) suggest that prostaglandin signaling may be
considered as an alternative or complementary target for intervention
with therapeutic potential.
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